Details of the Drug

General Information of Drug (ID: DMFFIDA)

Drug Name
Garetosmab
Indication
Disease Entry ICD 11 Status REF
Fibrodysplasia ossificans progressiva FB31.1 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DKP80T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inhibin beta A chain (INHBA) TTVB30D INHBA_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05394116) Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva. U.S.National Institutes of Health.
2 Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431.